Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Narayana Hrudayalaya Ltd. Share Price
Day's Range
Low
₹1,660.00
High
₹1,723.00
Price Summary
| Previous Close | ₹1,715.50 |
|---|---|
| Day's Range | ₹1,660.00 - ₹1,723.00 |
| Open | ₹1,662.30 |
| 52 Week Range | ₹1,589.00 - ₹2,093.30 |
| Volume | 68,724 |
| Market Cap | ₹0.03 |
| Previous Close | ₹1,713.80 |
|---|---|
| Day's Range | ₹1,662.00 - ₹1,721.00 |
| Open | ₹1,663.00 |
| 52 Week Range | ₹1,564.25 - ₹2,094.30 |
| Volume | 6,152 |
| Market Cap | ₹0.03 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1,178.96 |
|---|---|
| Market Cap (₹ in Mn) | 0.03 |
| Dividend Yield(%) | 0.27 |
| Price/Earning (TTM) | 41.62 |
| TTM EPS (₹) | 39.94 |
| P/E Ratio | 40.73 |
| Book Value(₹) | 7.16 |
| PAT Margin (%) | 10.26 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 16.20 |
| Trade Value ( ₹ in Lacs) | 105.43 |
|---|---|
| Market Cap (₹ in Mn) | 0.03 |
| Dividend Yield(%) | 0.27 |
| Price/Earning (TTM) | 41.62 |
| TTM EPS (₹) | 39.94 |
| P/E Ratio | 40.73 |
| Book Value(₹) | 7.16 |
| PAT Margin (%) | 10.26 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 16.20 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 9431.41 | 54829.77 |
| Expenses | N/A | N/A |
| PBT | 1172.73 | 9355.38 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 873.71 | 7906.31 |
About Narayana Hrudayalaya Ltd.
| Founded | 2000 |
|---|---|
| Managing Director | Emmanuel Rupert |
| NSE Symbol | NH |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,18,204.09 | 1,763.00 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,40,780.00 | 9,471.50 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,73,828.11 | 4,603.00 | 3,532.60 - 3,532.60 |
| Zydus Lifesciences Ltd. | 1,15,520.92 | 1,169.40 | 835.50 - 835.50 |
| Lenskart Solutions Ltd. | 1,13,228.83 | 669.25 | 0.00 - 0.00 |
| Apollo Hospitals Enterprise Ltd. | 1,12,367.71 | 7,939.35 | 6,696.50 - 6,696.50 |
| Laurus Labs Ltd. | 1,11,304.32 | 2,138.15 | 917.95 - 917.95 |
| Cipla Ltd. | 1,09,304.89 | 1,344.65 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,08,758.84 | 1,310.85 | 1,101.00 - 1,101.00 |
| Mankind Pharma Ltd. | 95,082.98 | 2,517.40 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Sai Parenterals informs about board meeting
Pursuant to Regulation 29 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sai Parenterals has informed that the Board Meeting of the Company will be held on Sunday, 01st November, 2026 at the registered office of the Company to consider, the following: 1. Un-audited financial results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026. 2. Limited Review Report (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026. 3. Any other business with the permission of the Chair. Further, with reference to our letter dated 30th September, 2026 regarding closure of trading window for dealing in shares of the Company, the company has informed that, pursuant to the Code of Conduct to Regulate, Monitor and Report Trading in Securities of the Company, the trading window shall continue to remain closed for all Designated Persons of the Company and their Immediate Relatives until 48 hours after the declaration of the Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026.
The above information is a part of company’s filings submitted to BSE.
Sai Parenterals informs about board meeting
OneSource Specialty Pharma informs about press release
Hester Biosciences informs about completion of tenure of independent director
Pursuant to provisions of Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), Hester Biosciences has informed that, Ameetkumar Desai (DIN: 00007116) has informed the Company of his decision not to seek re-appointment for a second consecutive term as an Independent Director upon completion of his current first tenure on 27 October 2026. Consequently, effective closure of business hours on 27 October 2026, Ameetkumar Desai ceases to be an Independent Director of the Company. The Company placed on record its appreciation for the valuable contribution and support provided him during his association with the Company. The details as required under SEBI Listing Regulation read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026, are enclosed.
The above information is a part of company’s filings submitted to BSE.
Chandra Bhagat Pharma informs about disclosure
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Narayana Hrudayalaya Ltd. is ₹1,715.50 as of 2026-10-27.
The market capitalisation of Narayana Hrudayalaya Ltd. is ₹33,964.77 as of 2026-10-26.
The 1-year return of Narayana Hrudayalaya Ltd. is -19.40% as of 2026-10-27.
The P/E ratio of Narayana Hrudayalaya Ltd. is 40.73 as of 2026-10-27.
The 52-week high and low of Narayana Hrudayalaya Ltd. are ₹2,093.30 and ₹1,589.00, respectively, as of 2026-10-27.
People Also Ask
Narayana Hrudayalaya Ltd. establishes partnerships by collaborating with regional governments to operate specialised public-private healthcare facilities. The hospital chain also works closely with medical technology firms to implement advanced, cost-effective surgical equipment across its network.
Narayana Hrudayalaya Ltd. provides extensive multi-specialty healthcare facilities, operating a network of over 40 hospitals and primary care clinics. The enterprise is globally ren
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
